Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

This study tests whether combining two drugs — fruquintinib (a targeted therapy) and sintilimab (an immunotherapy) — with or without radiation to the liver, can help patients with colorectal cancer that has spread to the liver and stopped responding to two prior lines of treatment. **You may be eligible if...** - You are an adult with confirmed colorectal adenocarcinoma that has spread to the liver - Your tumor is the MSS/pMMR type (a specific genetic subtype) - You have already received two rounds of standard chemotherapy that have not worked - You have measurable cancer on imaging and your organs are functioning well - You have not previously received immunotherapy (anti-PD-1/PD-L1) or fruquintinib - You have an expected survival of at least 3 months **You may NOT be eligible if...** - You have been diagnosed with another cancer within the past 3 years - You have received prior immunotherapy or fruquintinib - You have active autoimmune disease requiring systemic treatment - You are currently enrolled in another clinical study - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.